2ivv: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,613 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,613 edits
No edit summary
Line 1: Line 1:
[[Image:2ivv.gif|left|200px]]
{{Seed}}
[[Image:2ivv.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2ivv|  PDB=2ivv  |  SCENE=  }}  
{{STRUCTURE_2ivv|  PDB=2ivv  |  SCENE=  }}  


'''CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1'''
===CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1===




==Overview==
<!--
The RET proto-oncogene encodes a receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family of ligands. Loss-of-function mutations in RET are implicated in Hirschsprung disease, whereas activating mutations in RET are found in human cancers, including familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A and 2B. We report here the biochemical characterization of the human RET tyrosine kinase domain and the structure determination of the non-phosphorylated and phosphorylated forms. Both structures adopt the same active kinase conformation competent to bind ATP and substrate and have a pre-organized activation loop conformation that is independent of phosphorylation status. In agreement with the structural data, enzyme kinetic data show that autophosphorylation produces only a modest increase in activity. Longer forms of RET containing the juxtamembrane domain and C-terminal tail exhibited similar kinetic behavior, implying that there is no cis-inhibitory mechanism within the RET intracellular domain. Our results suggest the existence of alternative inhibitory mechanisms, possibly in trans, for the autoregulation of RET kinase activity. We also present the structures of the RET tyrosine kinase domain bound to two inhibitors, the pyrazolopyrimidine PP1 and the clinically relevant 4-anilinoquinazoline ZD6474. These structures explain why certain multiple endocrine neoplasia 2-associated RET mutants found in patients are resistant to inhibition and form the basis for design of more effective inhibitors.
The line below this paragraph, {{ABSTRACT_PUBMED_16928683}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 16928683 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_16928683}}


==About this Structure==
==About this Structure==
Line 43: Line 47:
[[Category: Tyrosine kinase]]
[[Category: Tyrosine kinase]]
[[Category: Tyrosine-protein kinase]]
[[Category: Tyrosine-protein kinase]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May  4 07:57:16 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 23:16:54 2008''

Revision as of 20:16, 28 July 2008

File:2ivv.png

Template:STRUCTURE 2ivv

CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1

Template:ABSTRACT PUBMED 16928683

About this Structure

2IVV is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Structure and chemical inhibition of the RET tyrosine kinase domain., Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, Santoro M, Ibanez CF, McDonald NQ, J Biol Chem. 2006 Nov 3;281(44):33577-87. Epub 2006 Aug 23. PMID:16928683

Page seeded by OCA on Mon Jul 28 23:16:54 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "https://proteopedia.org/index.php?title=2ivv&oldid=718285"